Obesity and associated cardiovascular risk factors in Iranian children: a cross-sectional study

Anahita Hamidi1, Hossein Fakhrzadeh, Alireza Moayyeri

  • 1Endocrinology and Metabolism Research Center, Doctor Shariati Hospital, Tehran University of Medical Science, Tehran, Iran.

Insights

Childhood obesity in Iran is linked to increased cardiovascular risk factors like high triglycerides and blood pressure. Early prevention and control are crucial for public health.

Area of Science:

  • Pediatrics
  • Cardiology
  • Public Health

Background:

  • Obesity is a growing global health concern, particularly in developing nations.
  • Childhood obesity is associated with cardiovascular risk factors, but data from Iran is limited.
  • This study addresses the prevalence of cardiovascular risk factors in Iranian obese children.

Purpose of the Study:

  • To determine the frequency of cardiovascular risk factors in Iranian children.
  • To investigate the association between obesity severity and these risk factors.
  • To provide data on the relationship between childhood obesity and cardiovascular health in Iran.

Main Methods:

  • Screened 13,086 children (aged 7-12 years) for obesity.
  • Classified participants as overweight or obese using International Obesity Task Force criteria.
  • Assessed cardiovascular risk factors including lipid profiles, triglycerides, and blood pressure.

Main Results:

  • 338 obese and 194 overweight children were included.
  • Obese children showed significantly higher triglyceride and Apo-lipoprotein B levels.
  • 81.9% of obese and 75.4% of overweight children had at least one risk factor.

Conclusions:

  • High prevalence of cardiovascular risk factors in overweight/obese Iranian children.
  • Strong correlation between obesity severity and cardiovascular risk factors.
  • Urgent need for early prevention and control of childhood obesity.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...